Peter Lamie
YOU?
Author Swipe
View article: Prognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center
Prognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center Open
Background: Invasive aspergillosis (IA) is a life-threatening fungal infection that primarily affects immunocompromised individuals and has high morbidity and mortality rates, necessitating timely diagnosis and treatment. This study aimed …
View article: Prognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center
Prognostic Value of Serum and Bronchoalveolar Lavage Fluid Galactomannan Levels in Invasive Aspergillosis: An 8-Year Experience at a Tertiary Cancer Center Open
Background: Invasive aspergillosis (IA) is a life-threatening fungal infection that primarily affects immunocompromised individuals and has high morbidity and mortality rates, necessitating timely diagnosis and treatment. This study aimed …
View article: Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment: 30-Year Experience in Hematologic Malignancy Patients
Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment: 30-Year Experience in Hematologic Malignancy Patients Open
Background: Anti-mold azoles have improved the outcomes of invasive aspergillosis (IA) when used therapeutically, but they are extensively used as prophylaxis. There are limited data regarding the outcomes of patients with hematologic mali…
View article: Decreased Frequency and Improved Outcomes in Invasive Aspergillosis Caused by Aspergillus terreus After the Introduction of Anti-Mold Azole Agents: A 30-Year Study at a Tertiary Cancer Center
Decreased Frequency and Improved Outcomes in Invasive Aspergillosis Caused by Aspergillus terreus After the Introduction of Anti-Mold Azole Agents: A 30-Year Study at a Tertiary Cancer Center Open
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with hematological malignancy (HM) and hematopoietic stem cell transplant (HSCT) recipients. Aspergillus terreus is associated with worse outcomes th…
View article: P-1045. Decreasing Frequency of Invasive Aspergillus due to <i>Aspergillus terreus</i> Coinciding with the Introduction of Anti-Mold Azole Prophylaxis: A 30 Year Study of Invasive Aspergillosis at a Tertiary Cancer Center
P-1045. Decreasing Frequency of Invasive Aspergillus due to <i>Aspergillus terreus</i> Coinciding with the Introduction of Anti-Mold Azole Prophylaxis: A 30 Year Study of Invasive Aspergillosis at a Tertiary Cancer Center Open
Background Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with haematological malignancy (HM) patients and hematopoietic stem cell transplant (HSCT) recipients. A. terreus is well known to be more…
View article: P-1025. Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis: Thirty Year Experience in Hematologic Malignancy Patients
P-1025. Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis: Thirty Year Experience in Hematologic Malignancy Patients Open
Background In patients with haematologic malignancy (HM) and stem cell transplant recipients, Invasive Aspergillosis (IA) remains associated with a poor prognosis. Anti-mold azoles have improved the outcome of IA when used therapeutically …
View article: Procalcitonin Level Monitoring in Antibiotic De-Escalation and Stewardship Program for Patients with Cancer and Febrile Neutropenia
Procalcitonin Level Monitoring in Antibiotic De-Escalation and Stewardship Program for Patients with Cancer and Febrile Neutropenia Open
Objective: Serial procalcitonin (PCT) monitoring has been adopted to supplement clinical judgement and help guide antibiotic therapy as part of antimicrobial stewardship programs. PCT levels peak 24 to 48 h after infection onset and declin…
View article: 859. The Role of Procalcitonin in Antimicrobial De-escalation and Stewardship Program in Febrile Neutropenic Cancer Patients
859. The Role of Procalcitonin in Antimicrobial De-escalation and Stewardship Program in Febrile Neutropenic Cancer Patients Open
Background Serial procalcitonin (PCT) measurement has been adopted as an adjunct to clinical judgement to guide antibiotic therapy, prevent antibiotics overuse and endorse antimicrobial stewardship programs. PCT peaks at 24 to 48 hours, an…
View article: 363. A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia
363. A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia Open
Background The overuse of antibiotics has led to the emergence of antibiotic resistance that poses a significant threat particularly for the immunocompromised cancer patients. Hence, the empiric therapy with standard antibiotic could be su…
View article: Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period Open
Background: An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The long-term consequences of COVID-19 are not fully understood part…
View article: Author response: Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period
Author response: Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period Open
Article Figures and data Abstract Editor's evaluation Introduction Methods Results Discussion Data availability References Decision letter Author response Article and author information Metrics Abstract Background: An increasing number of …
View article: Long COVID in Cancer patients: Preponderance of Symptoms in Majority of Patients over Long Time Period
Long COVID in Cancer patients: Preponderance of Symptoms in Majority of Patients over Long Time Period Open
Background An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease in non-cancer patients. The long-term consequences of COVID-19 are not fully understood parti…
View article: 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period
300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period Open
Background An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease. The long-term consequences of COVID-19 are not fully understood and there is no clear consen…